UK regulator suspends Amgen's Tavneos for new patients over unreliable data

Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's rare-disease drug, Tavneos, to new patients, saying ​the main study supporting its approval was unreliable.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。